Nov 6 (Reuters) - FDA:
FDA: SIX ADDITIONAL AWARDEES UNDER THE COMMISSIONER’S NATIONAL PRIORITY VOUCHER (CNPV) PILOT PROGRAM
FDA: ZONGERTINIB FOR HER2 LUNG CANCER, DOSTARLIMAB FOR RECTAL CANCER SELECTED FOR SECOND BATCH OF NATIONAL PRIORITY VOUCHERS
FDA: CASGEVY FOR SICKLE CELL DISEASE, ORFORGLIPRON FOR OBESITY AND RELATED HEALTH CONDITIONS SELECTED FOR SECOND BATCH OF NATIONAL PRIORITY VOUCHERS
FDA: WEGOVY FOR OBESITY, BEDAQUILINE FOR DRUG-RESISTANT TUBERCULOSIS IN YOUNG CHILDREN SELECTED FOR SECOND BATCH OF NATIONAL PRIORITY VOUCHERS
((Reuters.Briefs@thomsonreuters.com;))